A Swedish study suggests that newer blood thinners called NOACs may help slow cognitive decline in patients with both Alzheimer’s disease and atrial fibrillation.
Key facts
- •The study examined over 7,300 patients with both Alzheimer’s disease and atrial fibrillation.
- •Researchers followed participants for up to 5 years to track cognitive scores and health events.
- •NOACs were associated with a slower rate of cognitive decline compared to warfarin or no treatment.
- •NOAC users had a lower risk of stroke, death, and fractures without an increased risk of major bleeding.
- •NOACs are considered easier to manage than warfarin, which requires routine blood monitoring and dietary restrictions.
A nationwide study published in the European Heart Journal indicates that non-vitamin K antagonist oral anticoagulants (NOACs) may offer cognitive benefits for Alzheimer’s patients who also have atrial fibrillation (AFib). Researchers found that these newer blood thinners were associated with a slower rate of cognitive decline compared to older treatments like warfarin or no anticoagulant therapy.
By the numbers
Study Methodology and Findings
Researchers analyzed data from over 7,300 individuals in Sweden who were diagnosed with Alzheimer’s disease and had a prior diagnosis of AFib. Using linked national registries, the team tracked cognitive function via the Mini-Mental State Examination (MMSE) and monitored health outcomes for up to five years. The study concluded that NOAC users experienced a modest but meaningful slowing in cognitive decline, while also showing lower risks of stroke, death, and fractures compared to those not taking blood thinners.
Comparison to Warfarin
The study suggests that NOACs are more predictable and safer than warfarin, which has historically been a common treatment for AFib. While warfarin users saw fewer strokes and deaths than non-users, they faced a higher risk of serious bleeding. In contrast, NOACs were associated with fewer strokes and less major bleeding, and they do not require the routine blood monitoring or strict dietary limitations associated with warfarin.
Clinical Implications
Experts suggest that AFib causes microscopic clots that lead to 'silent strokes,' which damage brain blood vessels and accelerate cognitive decline. By neutralizing these micro-clots, NOACs may protect brain tissue from ischemic damage. The findings may shift how physicians approach treatment, as the potential for neuroprotection and cognitive preservation could outweigh previous concerns regarding bleeding risks in elderly patients.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Healthline.
